Propecia generic launch lifts Dr Reddy's
This article was originally published in Scrip
Executive Summary
Shares of Dr Reddy's Laboratories spurted on Indian bourses after the company said that it had launched a generic version of Merck & Co's mild-to-moderate male pattern hair loss treatment, Propecia (finasteride), in the US.